- ورشة يوم الاثنين الموافق 16/4/2018 بعنوان
" Health Economic Learning Program "
Dr. Abdalla Abo Taleb
Learning Outcomes
This program will provide Attendees with the skills and knowledge to:-
Principles of Health Economics
Grasping the Role of Health Economics care
Understanding the Concept of Cost Effectivness and Modeling
Understand the role of economic evaluation in healthcare decision-machinig and health policy.
- ورشة يوم الخميس الموافق 19/4/2018 بعنوان
" Psoriasis, Psoriatic Arthritis , Ankylosing Spondylitis Management "
Dr. Medahat Abdelmalek
Dr. Allam Khaleel
مناقشة البروتوكولات العلاجية الصادرة عن مديرية الصيدلــة والصيدلــة الســــريريـــة
Learning Outcomes
Differentiate between )Secukinumab) as a new class of treatment and the available other Anti – TNFs.
Effectiveness in treatment of Psoriasis & SPA comparing with Anti –TNFs and other ILs inhibitors.
Structural damage prevention data in spondyloarthritis Patients.
Treatment Effect on the psoriatic & Spondyolathrithis Patients QOL.
Sustainability data
Safety
Dosing and adherence
Cost-effectiveness.
ورشة يوم الاثنين الموافق 30/4/2018 بعنوان
Updating Management in Rheumatoid Arthritis""
Dr. Sara Al-Adem
Dr. Bilal Jaafreh.
Learning Outcomes
To know all the data that support Etanerccept in treating RA patients and how Etanercept helps RA patients.
To know all updating data about new treatment Tofacitinib and what's the need for such drug to be found and also what's the need still uncovered in RA management.
- ورشة يوم الثلاثاء الموافق 15/5/2018 بعنوان
" A New era in the management of Diabetes "
Dr. Tareq salameh
Drug safety
الصيدلانية وفاء الخطيب
مناقشة بروتوكول السكري الصادر عن مديرية الصيدلــة
والصيدلــة الســــريريـــة/الصيدلانية السريرية اميمة العايد
Learning Outcomes
§Unmet Needs in T2D Management
§The Kidney: a Key Organ in T2D management
§Clinical Benefits of SGLT2 inhibition/ Dapagliflozin in RCT/ RWE setting
§ Importance of Early treatment intensification in Type 2 diabetes
§Dapagliflozin as add on to Metformin
§SGLT2 I vs. DPP4 Inhibitors & SUs
§SGLT2 I Safety including Renal & CV Safety
§Guidelines & Conclusion
§Ongoing Research to further understand Dapagliflozin Potential